keyword
https://read.qxmd.com/read/38360704/autophagy-inhibition-improves-the-targeted-radionuclide-therapy-efficacy-of-131-i-fap-2286-in-pancreatic-cancer-xenografts
#21
JOURNAL ARTICLE
Xingyu Liu, Danni Li, Tianbao Ma, Xiu Luo, Ye Peng, Tao Wang, Changjing Zuo, Jianming Cai
PURPOSES: Radiotherapy can induce tumor cell autophagy, which might impair the antitumoral effect. This study aims to investigate the effect of autophagy inhibition on the targeted radionuclide therapy (TRT) efficacy of 131 I-FAP-2286 in pancreatic cancer. METHODS: Human pancreatic cancer PANC-1 cells were exposed to 131 I-FAP-2286 radiotherapy alone or with the autophagy inhibitor 3-MA. The autophagy level and proliferative activity of PANC-1 cells were analyzed...
February 15, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38340243/nodal-metastasis-in-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-niftp
#22
JOURNAL ARTICLE
Alfredo Campennì, Liborio Torregrossa, Rosaria Maddalena Ruggeri, Petra Petranović Ovčariček, Massimiliano Siracusa, Luca Giovanella
The term noninvasive tumor with a follicular growth pattern and nuclear features of papillary thyroid cancer (NIFTP) is used to describe a tumor currently considered as a pre-malignant lesion for which a conservative therapeutic approach (i.e., lobectomy without radioiodine therapy) is strongly suggested. However, some patients with NIFTP and loco-regional or distant metastases have been already reported. We present an adult male patient with a final histological diagnosis of NIFTP and lymph node metastasis noted at post-therapy whole-body scintigraphy performed some days after radioiodine therapy...
February 10, 2024: Endocrine
https://read.qxmd.com/read/38327753/b7-h3-inhibitors-in-oncology-clinical-trials-a-review
#23
REVIEW
Kavanya Feustel, Jared Martin, Gerald S Falchook
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131 I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted...
February 2024: Journal of immunotherapy and precision oncology
https://read.qxmd.com/read/38319674/incidence-of-subclinical-and-overt-hypothyroidism-in-children-treated-with-131i-mibg-a-systematic-review-and-meta-analysis
#24
JOURNAL ARTICLE
Francesco Fiz, Tommaso Piticchio, Gianluca Bottoni, Stefania Sorrentino, Martina Fragola, Virginia Livellara, Pierpaolo Trimboli, Arnoldo Piccardo
INTRODUCTION: Treatment with [131 I]mIBG is commonly used in pediatric metastatic neuroblastoma (NB); however, unbound [131 I]I might be taken up by the thyroid, causing hypothyroidism. To prevent this occurrence, thyroid blockade with iodine salts is commonly used; despite this precaution, thyroid dysfunction still occurs. This review and meta-analysis aim to clarify the mean frequency of hypothyroidism in children with NB treated with [131 I]mIBG and to investigate the possible causes...
February 6, 2024: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/38313265/aurora-kinase-a-inhibition-enhances-dna-damage-and-tumor-cell-death-with-131i-mibg-therapy-in-high-risk-neuroblastoma
#25
Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Steven G DuBois, Nicole Nasholm, Daphne Haas-Kogan, Katherine K Matthay, William A Weiss, Clay Gustafson, Youngho Seo
Background Neuroblastoma is the most common extra-cranial pediatric solid tumor. 131 I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical highly specific for neuroblastoma tumors, providing potent radiotherapy to widely metastatic disease. Aurora kinase A (AURKA) plays a role in mitosis and stabilization of the MYCN protein in neuroblastoma. Here we explore whether AURKA inhibition potentiates a response to MIBG therapy. Results Using an in vivo model of high-risk neuroblastoma, we demonstrated a marked combinatorial effect of 131 I-MIBG and alisertib on tumor growth...
January 18, 2024: Research Square
https://read.qxmd.com/read/38308714/tadalafil-versus-tamsulosin-as-combination-therapy-with-5-alpha-reductase-inhibitors-in-benign-prostatic-hyperplasia-urinary-and-sexual-outcomes
#26
RANDOMIZED CONTROLLED TRIAL
Ahmed Tawfik, Mohammed Abo-Elenen, Mohammed Gaber, Ahmed El-Abd, Ahmed Zoeir, Sayed Saad, Intessar Sultan, Ayman Ghoneim
PURPOSE: To compare the urological and sexual outcomes of using either tamsulosin/finateride or tadalafil/finasteride as combination therapies in patients with large prostate. PATIENTS AND METHODS: Selection criteria included prostate volume > 40 ml and IPSS > 7. Patients with severe erectile dysfunction (IIEF-erectile functions ≤ 10) were excluded. Patients were randomized into group I (tamsulosin/finasteride) and group II (tadalafil/finasteride)...
February 3, 2024: World Journal of Urology
https://read.qxmd.com/read/38304356/simultaneous-metastases-of-papillary-thyroid-carcinoma-and-neuroendocrine-tumor-of-the-cecum-to-cervical-lymph-nodes-a-case-report
#27
Matija Romić, Ivan Blažeković, Neven Mateša, Maja Franceschi, Ines Šiško-Markoš, Zvonko Kusić, Ana Fröbe, Tomislav Jukić
We present a case of a patient with simultaneous cervical lymph node metastasis of papillary thyroid cancer (PTC) and cecum neuroendocrine tumor (NET). A 45-year-old male patient with the diagnosis of metastatic NET of the cecum underwent fine needle aspiration (FNA) of a positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG PET) positive nodule in the left thyroid lobe. Due to FNA finding suspect of PTC, the patient underwent total thyroidectomy with central neck dissection. Histopathologic finding revealed PTC of the left thyroid lobe and small solitary lymph node PTC metastasis in the central neck region...
April 2023: Acta Clinica Croatica
https://read.qxmd.com/read/38291522/correlation-between-remnant-thyroid-gland-i-131-uptake-and-serum-thyroglobulin-levels-can-we-rely-on-i-131-whole-body-scans
#28
JOURNAL ARTICLE
Sang Hyun Hwang, KwanHyeong Jo, Jongtae Cha, Chun Goo Kang, Jiyoung Wang, Hojin Cho, Won Jun Kang, Arthur Cho
BACKGROUND: I-131 treatment (RAI) decision relies heavily on serum thyroglobulin (Tg) levels, as higher Tg levels are assumed to be correlated with higher I-131 uptake. Tg elevation, negative iodine scintigraphy (TENIS) definition is becoming more clinically relevant as alternative treatment methods are available. This study examined the correlation between Tg levels with I-131 uptake in remnant thyroid gland to evaluate the reliability of serum Tg levels in predicting I-131 uptake. METHODS: From March 2012 to July 2019, 281 papillary thyroid cancer patients treated with 150 mCi RAI were retrospectively enrolled...
January 30, 2024: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://read.qxmd.com/read/38277114/factors-predicting-remission-in-hyperthyroid-patients-after-low-dose-i-131-therapy-20%C3%A2-years-retrospective-study-from-a-tertiary-care-hospital
#29
JOURNAL ARTICLE
Shrinivas Yuvan S, Subramanyam Padma, Palaniswamy Shanmuga Sundaram
OBJECTIVE: To assess the therapeutic outcome and factors predicting remission in hyperthyroid patients treated with low-dose I-131 (radioactive iodine) from a tertiary care hospital in South India. METHODS: This 20-year single-institutional retrospective study was carried out on 3891 hyperthyroid adult patients. Only those patients with complete clinical records were audited. Selection criteria were based on patients with scintigraphic diagnosis of either Graves' disease (GD), toxic multinodular goitre (TMNG) or autonomous toxic nodule (ATN) and the records of those who received low-dose I-131 therapy (LDT) between March 2000 and 2020 at Amrita Institute, Cochin were analysed...
January 26, 2024: Annals of Nuclear Medicine
https://read.qxmd.com/read/38276075/tumor-burden-of-iodine-avid-bone-metastatic-thyroid-cancer-identified-via-18-f-sodium-fluoride-pet-ct-imaging
#30
JOURNAL ARTICLE
Carmela Nappi, Emilia Zampella, Valeria Gaudieri, Fabio Volpe, Leandra Piscopo, Carlo Vallone, Leonardo Pace, Andrea Ponsiglione, Simone Maurea, Emanuele Nicolai, Alberto Cuocolo, Michele Klain
BACKGROUND: Patients with differentiated thyroid cancer (DTC) are referred to radioactive 131 I (RAI) therapy and post-therapy 131 I whole-body scintigraphy (WBS) to identify local and/or remote metastases. Positron emission tomography (PET)/computed tomography (CT) imaging with 18 F-fluoro-D-glucose (FDG) or 18 F-sodium fluoride (NaF) may also be used with these patients for the evaluation of bone metastases. We compared the role of 18 F-NaF PET/CT and 18 F-FDG-PET/CT in patients with DTC and documented bone metastases at post-therapy WBS...
January 19, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38275937/peripheral-neuropathy-in-virologically-suppressed-people-living-with-hiv-evidence-from-the-pivot-trial
#31
JOURNAL ARTICLE
Anna L Schuldt, Henry Bern, Melanie Hart, Mark Gompels, Alan Winston, Amanda Clarke, Fabian Chen, Wolfgang Stöhr, Amanda Heslegrave, Nicholas I Paton, Axel Petzold, Alejandro Arenas-Pinto
The aim of this study is to identify the factors associated with peripheral neuropathy and to explore neurofilament light chain (NfL) as a biomarker for peripheral neuropathy (PN) in effectively virologically suppressed adults living with HIV. All protease inhibitor monotherapy versus ongoing triple therapy in the long-term management of HIV infection (PIVOT) trial participants with data on PN at baseline were included in the study. NfL plasma levels (pNfL) were measured in a sub-set of participants. Multivariable logistic regression was used to examine the associations of PN with potential risk factors (including age, sex, nadir CD4 cell count, history of dideoxynucleoside (d-drugs) exposure, and blood glucose levels) and NfL levels...
December 19, 2023: Viruses
https://read.qxmd.com/read/38250038/peptide-receptor-radionuclide-therapy-combinations-for-neuroendocrine-tumours-in-ongoing-clinical-trials-status-2023
#32
REVIEW
Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, Irene Virgolini
A growing body of literature reports on the combined use of peptide receptor radionuclide therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with perhaps increased safety issues. Combination treatments to enhance PRRT outcome are based on improved tumour perfusion, upregulation of somatostatin receptors (SSTR), radiosensitization with DNA damaging agents or targeted therapies. Several Phase 1 or 2 trials are currently recruiting patients in combined regimens. The combination of PRRT with cytotoxic chemotherapy, capecitabine and temozolomide (CAPTEM), seems to become clinically useful especially in pancreatic neuroendocrine tumours (pNETs) with acceptable safety profile...
2024: Theranostics
https://read.qxmd.com/read/38223058/flow-augmentation-sta-mca-bypass-for-acute-and-subacute-ischemic-stroke-due-to-internal-carotid-artery-occlusion-and-the-role-of-advanced-neuroimaging-with-hemodynamic-and-flow-measurement-in-the-decision-making-preliminary-data
#33
JOURNAL ARTICLE
Martina Sebök, Lara Maria Höbner, Jorn Fierstra, Tilman Schubert, Susanne Wegener, Zsolt Kulcsár, Andreas R Luft, Luca Regli, Giuseppe Esposito
BACKGROUND: A major clinical challenge is the adequate identification of patients with acute (<1 week) and subacute (1-6 weeks) ischemic stroke due to internal carotid artery (ICA) occlusion who could benefit from a surgical revascularization after a failure of endovascular and/or medical treatment. Recently, two novel quantitative imaging modalities have been introduced: (I) quantitative magnetic resonance angiography (qMRA) with non-invasive optimal vessel analysis (NOVA) for quantification of blood flow in major cerebral arteries (in mL/min), and (II) blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging to assess cerebrovascular reactivity (CVR)...
January 3, 2024: Quantitative Imaging in Medicine and Surgery
https://read.qxmd.com/read/38214553/optimal-cumulative-i-131-activity-in-metastatic-differentiated-thyroid-cancer-balancing-efficacy-and-adverse-events
#34
JOURNAL ARTICLE
Mangu Srinivas Bharadwaj, Sanjana Ballal, Chandrasekhar Bal
BACKGROUND: The optimal cumulative activity (CA) of I-131 therapy for patients with metastatic differentiated thyroid cancer (mDTC) remains contentious. This study aimed to determine the maximum CA of I-131 that could be administered without a significant increase in adverse events (AEs) by analyzing a long-term cohort of patients. METHODS: Data from mDTC patients treated with I-131 therapy and followed for at least two years from 1967 to 2019 were reviewed. Patients were categorized into three groups based on the received CA: Group-A (≤600mCi), Group-B (>600-1000mCi), and Group-C (>1000mCi)...
January 12, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38213166/radiopharmaceuticals-a-new-vista-for-diagnosis-and-treatment-of-thyroid-cancer
#35
JOURNAL ARTICLE
Siddhi Vernekar, Roja Rani Budha, Rajasekhar Reddy Alavala
Radiopharmaceuticals are in the diagnosis and treatment of cancerous and noncancerous diseases, and a hope for optimistic effort in the field of nuclear medicine. They play a crucial role in clinical nuclear medicine by providing a tool to comprehend human disease and create efficient treatments. A detailed analysis is provided regarding the crux of molecular imaging including PET and SPECT overview for the detection of cancers. For a specified understanding of radiation therapy, topics include ranging from the selection of radionuclide to its development and manufacture, and dosage requirements to establishing the importance of I- 131 Radiotherapy in thyroid cancer...
January 11, 2024: Current Radiopharmaceuticals
https://read.qxmd.com/read/38207010/a-systematic-review-of-clinical-applications-of-anti-cd20-radioimmunotherapy-for-lymphoma
#36
JOURNAL ARTICLE
Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky
PURPOSE: The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biopharma) and 131 I-tositumomab (131-IT, Bexxar, GlaxoSmithKline) both target CD20...
January 11, 2024: Oncologist
https://read.qxmd.com/read/38202124/an-artificial-intelligence-system-for-optimizing-radioactive-iodine-therapy-dosimetry
#37
JOURNAL ARTICLE
Michalis F Georgiou, Joshua A Nielsen, Rommel Chiriboga, Russ A Kuker
Thyroid cancer, specifically differentiated thyroid carcinoma (DTC), is one of the most prevalent endocrine malignancies worldwide. Radioactive iodine therapy (RAIT) using I-131 has been a standard-of-care approach for DTC due to its ability to ablate remnant thyroid disease following surgery, thus reducing the risk of recurrence. It is also used for the treatment of iodine-avid metastases. RAIT dosimetry can be employed to determine the optimal treatment dose of I-131 to effectively treat cancer cells while safeguarding against undesirable radiation effects such as bone marrow toxicity or radiation pneumonitis...
December 25, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38200650/nectin-4-expression-in-a-subset-of-cutaneous-adnexal-carcinomas-a-potential-target-for-therapy-with-enfortumab-vedotin
#38
JOURNAL ARTICLE
Woo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan, Phyu P Aung, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4 that is used to treat urothelial carcinoma. Nectin-4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin-4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. METHODS: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody...
January 10, 2024: Journal of Cutaneous Pathology
https://read.qxmd.com/read/38172344/stimulating-thyroglobulin-to-tsh-ratio-predict-long-term-efficacy-of-131-i-therapy-in-patients-with-differentiated-thyroid-cancer-after-total-thyroidectomy-a-retrospective-study
#39
JOURNAL ARTICLE
Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng
OBJECTIVE: This study utilized the stimulated thyroglobulin (sTg) to thyroid stimulating hormone (TSH) ratio to predict the long-term efficacy of 131 I therapy in patients with moderate-to-high-risk differentiated thyroid cancer (DTC). METHODS: This study retrospectively analyzed 960 DTC patients with a median follow-up time of 30 months (6-92 months). The median age was 44 years. All patients underwent total thyroidectomy, lymph node dissection, and at least one 131 I therapy...
January 3, 2024: Endocrine
https://read.qxmd.com/read/38164565/diagnostic-performance-of-18-f-tfb-pet-ct-compared-with-therapeutic-activity-131-i-iodine-spect-ct-and-18-f-fdg-pet-ct-in-recurrent-differentiated-thyroid-carcinoma
#40
JOURNAL ARTICLE
David Ventura, Matthias Dittmann, Florian Büther, Michael Schäfers, Kambiz Rahbar, Daniel Hescheler, Michael Claesener, Philipp Schindler, Burkhard Riemann, Robert Seifert, Wolfgang Roll
[18 F]tetrafluoroborate ([18 F]TFB) is an emerging PET tracer with excellent properties for human sodium iodide symporter (NIS)-based imaging in patients with differentiated thyroid cancer (DTC). The aim of this study was to compare [18 F]TFB PET with high-activity posttherapeutic [131 I]iodine whole-body scintigraphy and SPECT/CT in recurrent DTC and with [18 F]FDG PET/CT in suspected dedifferentiation. Methods: Twenty-six patients treated with high-activity radioactive [131 I]iodine therapy (range, 5.00-10...
December 21, 2023: Journal of Nuclear Medicine
keyword
keyword
97180
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.